Cybrexa Therapeutics
Ranjit Bindra has an extensive and diverse work experience. Ranjit is currently serving as the Harvey and Kate Cushing Professor and Vice Chair for Translational Research at the Yale University School of Medicine since September 2021. Ranjit has previously held positions as a Professor, Associate Professor, and Assistant Professor at the same institution.
In addition to their academic roles, Bindra has also been involved in several biotech companies. Ranjit is a Co-Founder of Modifi Bio since April 2021, as well as B3 Therapeutics, Alphina Therapeutics, and Cybrexa Therapeutics.
Before joining Yale, Bindra worked as a Physician-Scientist in Radiation Oncology at MSKCC from July 2008 to June 2012. Ranjit conducted research focused on understanding the molecular determinants of the cellular response to ionizing radiation and developing radiosensitizers for the treatment of brain tumors.
Bindra's career in the medical field began as an MD/PhD Student at Yale University School of Medicine in 2000, where they completed their studies in 2007.
Additionally, Bindra is a Co-Founder of Helix Therapeutics, LLC, a company that developed oligonucleotide-based therapies for correcting gene mutations in blood stem cells. Ranjit was involved with Helix Therapeutics from January 2005 to May 2012.
Ranjit Bindra completed their Bachelor of Science degree in Molecular Biophysics and Biochemistry from Yale University, from the year 1994 until 1998. Subsequently, they pursued further education at Yale University School of Medicine and earned a combined MD/PhD degree in Cancer Biology, spanning from the year 2000 to 2007.
This person is not in the org chart
Cybrexa Therapeutics
1 followers
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.